iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer
May 09 2022 - 8:00AM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of
next-generation biopharmaceuticals and pioneer of the
sustainable
FastPharming®
Manufacturing
System, announced today a poster presentation on IBIO-101, the
Company's monoclonal antibody candidate for the treatment of solid
tumors. The presentation will take place at Frontiers in Cancer
Immunotherapy 2022 by the New York Academy of Sciences from May
9-11.
Preclinical evaluation of IBIO-101, produced
with iBio’s FastPharming and
GlycaneeringSM Systems, showed equivalent efficacy
and potency compared with this IL-2 sparing anti-CD25 antibody made
using traditional mammalian cell culture methods (RTX-003 from
RubrYc Therapeutics, Inc.). Additionally, iBio’s proprietary
afucosylation technology enabled the engineering of a more potent
version without incremental intellectual property access
costs. The Company now plans to advance its
Glycaneered anti-CD25 monoclonal antibody for the
depletion of regulatory T cells (“Tregs”) to the clinic next
year.
Dillon Phan, PhD, iBio’s Vice President and Head
of Early Research and Development, will present the poster, titled
"Plant-Based Expression and Glyco-Engineering of Novel IL-2
Signaling Permissive Anti-CD25 Antibodies for Effective Treg
Depletion in Cancer", which highlights:
- A CD25 epitope-survey using a novel
artificial intelligence/machine learning platform to identify one
epitope and corresponding antibodies with particularly high
antibody-dependent cellular cytotoxicity (“ADCC”) activity.
- The production of a
Glycaneered version of IBIO-101, which
significantly increased effector function resulting from
afucosylation using a deltaXT/FT N. benthamiana host compared with
a fucoslyated form of the molecule.
- Binding of IBIO-101 specifically to
CD25+ cancerous cells with high affinity.
- Preserved IL-2 signaling to
effector T cells via pSTAT5.
- Potent ADCC activity in killing
cancer cells.
More information on cancer drug discovery and
development with plants may be accessed in an article on the topic
here.
About iBio, Inc.
iBio is a developer of next-generation
biopharmaceuticals and a pioneer in sustainable, plant-based
biologics manufacturing. Its
FastPharming® System combines
vertical farming, automated hydroponics, and novel glycosylation
technologies to rapidly deliver high-quality monoclonal antibodies,
vaccines, bioinks and other proteins. iBio is developing
proprietary biopharmaceuticals for the treatment of cancers, as
well as fibrotic and infectious diseases. The Company’s
wholly-owned subsidiary, iBio CDMO LLC, provides
FastPharming Contract Development and
Manufacturing Services along with Glycaneering
Development Services™ for advanced recombinant protein design. For
more information, visit www.ibioinc.com.
Forward-Looking Statements
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the
FastPharming Manufacturing System; the ability to
produce IL-2 sparing anti-CD25 antibody using the
FastPharming Manufacturing System with efficacy
and potency equivalent to other manufacturing systems; the ability
to produce a more potent version of IL-2 sparing anti-CD25
antibody; and the ability to file an IND for the anti-CD25
monoclonal antibody. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the factors discussed in the Company’s
filings with the SEC including the Company’s Annual Report on Form
10-K for the year ended June 30, 2021 and the Company’s subsequent
filings with the SEC on Forms 10-Q and 8-K. The information in this
release is provided only as of the date of this release, and the
Company undertakes no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024